Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16

Nanomedicine (Lond). 2024;19(21-22):1779-1799. doi: 10.1080/17435889.2024.2372243. Epub 2024 Aug 14.

Abstract

Aim: To develop a trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against hand foot and mouth disease (HFMD) and assess its immunogenicity in mice.Materials & methods: Trivalent plasmid carrying the VP1 and VP2 genes of EV-A71, VP1 gene of CV-A16 was encapsulated in Chitosan-TPP nanoparticles through ionic gelation. In vitro characterization and in vivo immunization studies of the CS-TPP-NPs (pIRES-VP121) were performed.Results: Mice administered with CS-TPP NPs (pIRES-VP121) intramuscularly were observed to have the highest IFN-γ response. Sera from mice immunized with the naked pDNA and CS-TPP-NPs (pIRES-VP121) demonstrated good viral clearance against wild-type EV-A71 and CV-A16 in RD cells.Conclusion: CS-TPP-NPs (pIRES-VP121) could serve as a prototype for future development of multivalent HFMD DNA vaccine candidates.

Keywords: DNA; immunology/infectious diseases; nanoparticles; vaccines; viruses.

Plain language summary

[Box: see text].

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Capsid Proteins / chemistry
  • Capsid Proteins / immunology
  • Chitosan* / chemistry
  • Enterovirus A, Human* / immunology
  • Female
  • Hand, Foot and Mouth Disease* / immunology
  • Hand, Foot and Mouth Disease* / prevention & control
  • Humans
  • Interferon-gamma / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles* / chemistry
  • Plasmids
  • Polyphosphates
  • Vaccines, DNA* / administration & dosage
  • Vaccines, DNA* / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology

Substances

  • Vaccines, DNA
  • Chitosan
  • Viral Vaccines
  • Interferon-gamma
  • triphosphoric acid
  • Capsid Proteins
  • Polyphosphates